Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
Thierry André(Sorbonne Université), Sara Lonardi(Istituto Oncologico Veneto), Ming Lei(Bristol-Myers Squibb (United States)), Tian Chen(Sorbonne Université), Michael Schenker(Sorbonne Université), Jaafar Bennouna(Sorbonne Université), María Luisa Limón(Sorbonne Université), Guillermo Méndez(Sorbonne Université), Lars Henrik Jensen(Sorbonne Université), Elvis Cela(Sorbonne Université), Heinz‐Josef Lenz(University of Southern California), Timuçin Çil(Sorbonne Université), Rocio García‐Carbonero(Hospital Universitario 12 De Octubre), Giampaolo Tortora(Università Cattolica del Sacro Cuore), Myriam Chalabi(Dutch Cancer Society), Christelle de la Fouchardière, Takayuki Yoshino(University of Tsukuba), Maria Ignez Braghiroli(Universidade de São Paulo), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Jin Li(Fudan University), Matthew Dixon(Sorbonne Université), Rohit Joshi(Sorbonne Université), Elena Élez(Vall d'Hebron Hospital Universitari), Sandzhar Abdullaev(Bristol-Myers Squibb (United States)), Laëtitia Dahan, José Luis Manzano Mozo(Sorbonne Université), Eray Goekkurt(Sorbonne Université)
Cited by 208
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k